News Releases

Search

November 22, 2021
Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass. and BOULDER, Colo. , Nov. 22, 2021 /PRNewswire/ -- Cogent Biosciences , Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins , Chief Executive Officer and President will participate
Read More
November 10, 2021
Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results
Initiated SUMMIT, a Phase 2 clinical trial of bezuclastinib for Nonadvanced Systemic Mastocytosis (NonAdvSM) patients PEAK, a Phase 3 clinical trial of bezuclastinib and sunitinib for Gastrointestinal Stromal Tumor (GIST) patients, remains on track for 2021 start following positive FDA discussions
Read More
November 2, 2021
Cogent Biosciences to Present Virtually at Jefferies London Healthcare Conference 2021
CAMBRIDGE, Mass. and BOULDER, Colo. , Nov. 2, 2021 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will
Read More
October 7, 2021
Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain Penetration
Currently enrolling APEX, a Phase 2 clinical study of bezuclastinib (CGT9486) for patients with Advanced Systemic Mastocytosis (AdvSM) On track to initiate clinical trials of bezuclastinib for patients with Non-Advanced Systemic Mastocytosis (NonAdvSM) and Gastrointestinal Stromal Tumors (GIST) in
Read More
October 1, 2021
Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference
CAMBRIDGE, Mass. and BOULDER, Colo. , Oct. 1, 2021 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the Company will present preclinical data on bezuclastinib at the
Read More
August 16, 2021
Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results
Initiated Phase 2 open-label clinical study (APEX) for bezuclastinib (CGT9486) in patients with Advanced Systemic Mastocytosis (AdvSM) SUMMIT study for patients with Non-Advanced Systemic Mastocytosis (NonAdvSM) on track to start 2H 2021 following recent positive interactions with FDA Formed Cogent
Read More
July 27, 2021
Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021
CAMBRIDGE, Mass. and BOULDER, Colo. , July 27, 2021 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will
Read More
June 29, 2021
Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021
CAMBRIDGE, Mass. and BOULDER, Colo. , June 29, 2021 /PRNewswire/ --  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will
Read More
May 26, 2021
Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021
CAMBRIDGE, Mass. and BOULDER, Colo. , May 26, 2021 /PRNewswire/ -- Cogent Biosciences , Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present
Read More
May 12, 2021
Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results
IND cleared for Phase 2 study of CGT9486, a selective mutant KIT inhibitor, in Advanced Systemic Mastocytosis patients John Robinson, PhD appointed as Chief Scientific Officer to lead newly created Cogent Research team Evan Kearns, JD joined Cogent as Chief Legal Officer Ended Q1 2021 with $230.7
Read More
Displaying 1 - 10 of 16
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.
Print Page
RSS
Email Alerts
Search